The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab: potential role of the stanniocalcin-2 / PAPP-A / IGFBP-4 axis

BACKGROUND: Patients with inflammatory bowel disease (IBD) present with reduced serum insulin-like growth factor I (IGF-I). Anti-inflammatory treatment with prednisolone or infliximab ameliorates symptoms and increases circulating IGF-I, but prednisolone induces catabolism, whereas infliximab may pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hjortebjerg, Rikke, Thomsen, Karen L., Agnholt, Jørgen, Frystyk, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547608/
https://www.ncbi.nlm.nih.gov/pubmed/31159802
http://dx.doi.org/10.1186/s12876-019-1000-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547608/
https://www.ncbi.nlm.nih.gov/pubmed/31159802
http://dx.doi.org/10.1186/s12876-019-1000-6

Ejemplares similares